S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NYSE:ZYME

Zymeworks (ZYME) Stock Forecast, Price & News

$8.25
-0.17 (-2.02%)
(As of 05/26/2023 ET)
Compare
Today's Range
$8.20
$8.48
50-Day Range
$8.07
$10.22
52-Week Range
$4.11
$10.80
Volume
353,555 shs
Average Volume
489,390 shs
Market Capitalization
$529.40 million
P/E Ratio
3.19
Dividend Yield
N/A
Price Target
$12.44

Zymeworks MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
50.8% Upside
$12.44 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Zymeworks in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$1.60 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.31) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

275th out of 1,018 stocks

Pharmaceutical Preparations Industry

113th out of 498 stocks


ZYME stock logo

About Zymeworks (NYSE:ZYME) Stock

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

ZYME Stock News Headlines

Zymeworks (ZYME) Gets a Buy from Stifel Nicolaus
"The $51 Billion Laser Revolution"
See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>
Zymeworks (NYSE:ZYME) Trading Up 4.3% After Analyst Upgrade
Zymeworks (NYSE:ZYME) PT Raised to $18.00 at Citigroup
What 6 Analyst Ratings Have To Say About Zymeworks
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Zymeworks (NYSE:ZYME) Shares Down 6.9%
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Zymeworks (NYSE:ZYME) Shares Gap Up on Analyst Upgrade
What Wall Street expects from Zymeworks's earnings
Zymeworks (ZYME) to Release Earnings on Monday
Comparing Zymeworks (NYSE:ZYME) & PepGen (NASDAQ:PEPG)
Zymeworks (NYSE:ZYME) Stock Price Up 4.7%
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

ZYME Company Calendar

Last Earnings
5/08/2023
Today
5/27/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:ZYME
Employees
455
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.44
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+50.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$124.34 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$412.48 million
Book Value
$5.35 per share

Miscellaneous

Free Float
63,125,000
Market Cap
$529.40 million
Optionable
Optionable
Beta
0.97

Key Executives

  • Ken Galbraith
    Chairman & Chief Executive Officer
  • Neil A. KlompasNeil A. Klompas
    President & Chief Operating Officer
  • Christopher Astle
    Chief Financial Officer & Senior Vice President
  • Mark Hollywood
    EVP, Head-Technical & Manufacturing Operations
  • Kaycia Wilde
    Vice President-Clinical Operations













ZYME Stock - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZYME shares.
View ZYME analyst ratings
or view top-rated stocks.

What is Zymeworks' stock price forecast for 2023?

9 analysts have issued 1-year target prices for Zymeworks' stock. Their ZYME share price forecasts range from $8.00 to $19.00. On average, they anticipate the company's share price to reach $12.44 in the next twelve months. This suggests a possible upside of 50.8% from the stock's current price.
View analysts price targets for ZYME
or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2023?

Zymeworks' stock was trading at $7.86 at the beginning of 2023. Since then, ZYME stock has increased by 5.0% and is now trading at $8.25.
View the best growth stocks for 2023 here
.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ZYME earnings forecast
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) announced its earnings results on Monday, May, 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.27. The company earned $35.58 million during the quarter, compared to analysts' expectations of $8.73 million. Zymeworks had a trailing twelve-month return on equity of 77.65% and a net margin of 38.69%.

What ETFs hold Zymeworks' stock?

ETFs with the largest weight of Zymeworks (NYSE:ZYME) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Biotechnology ETF (IBB),

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (15.73%), Perceptive Advisors LLC (5.26%), Rubric Capital Management LP (4.45%), Credit Suisse AG (3.87%), Farallon Capital Management LLC (3.12%) and BlackRock Inc. (1.17%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Diana Hausman, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson.
View institutional ownership trends
.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $8.25.

How much money does Zymeworks make?

Zymeworks (NYSE:ZYME) has a market capitalization of $529.40 million and generates $412.48 million in revenue each year. The company earns $124.34 million in net income (profit) each year or $2.59 on an earnings per share basis.

How many employees does Zymeworks have?

The company employs 455 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (302) 274-8744, via email at ir@zymeworks.com, or via fax at 604-737-7077.

This page (NYSE:ZYME) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -